CNM-Au8(CNM-Au8) - 在研适应症：肌萎缩侧索硬化，复发性多发性硬化，原发性进行性多发性硬化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nanocrystalline gold、CNM AU 8

靶点-

作用方式

调节剂

作用机制

免疫调节剂

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病+ [2]

在研适应症

肌萎缩侧索硬化复发性多发性硬化原发性进行性多发性硬化+ [2]

非在研适应症

复发-缓解型多发性硬化视神经脊髓炎帕金森病

原研机构

Clene Nanomedicine, Inc.

在研机构

Clene Nanomedicine, Inc.Clene, Inc.

非在研机构

Clene Australia Pty Ltd.

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式Au

InChIKeyPCHJSUWPFVWCPO-UHFFFAOYSA-N

CAS号7440-57-5

关联

13

项与 CNM-Au8 相关的临床试验

NCT05299658

/ Active, not recruiting临床2期

An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.

开始日期2021-11-13

申办/合作机构

Clene Nanomedicine, Inc.

NCT04626921

/ Completed临床2/3期

VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Open-label, long-term extension study available to participants who have completed CNMAu8.201.

开始日期2020-10-22

申办/合作机构

Clene Nanomedicine, Inc.

[+1]

NCT04414345

/ Completed临床2/3期IIT

HEALEY ALS Platform Trial - Regimen C CNM-Au8

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.

开始日期2020-07-30

申办/合作机构

The Massachusetts General Hospital

[+1]

100 项与 CNM-Au8 相关的临床结果

登录后查看更多信息

100 项与 CNM-Au8 相关的转化医学

登录后查看更多信息

100 项与 CNM-Au8 相关的专利（医药）

登录后查看更多信息

324,778

项与 CNM-Au8 相关的文献（医药）

2025-12-31·Sustainable Environment

Geochemistry and human health risks of heavy metals in soils from gold mineralized Birimian rocks in Southwestern Burkina Faso

作者: Sako, Aboubakar ; Coulibaly, Kadidiatou

This study aims to identify sources and health risks of a series of heavy metals in topsoil from Birimian basement rocks in southwestern Burkina Faso.Concentrations of geochem. data of 66 samples were determined using ICP-MS.R-mode factor anal., Sediment/Soil Quality Guidelines and ecol. and human health risk indexes were used to investigate the associations between the heavy metals and their impacts on the ecosystem and the local population.It can be noted that 78, 83 and 85% of the samples had maximum concentrations of Ni, Cr and As higher than their resp. SQG indexes.The mean concentrations of these key contaminants were 42.09, 233.1 and 7.72 mg/kg for Ni, Cr and As, resp.According to the median effect range mean quotient (MERMQ), 87.9% (MERMQ >0.11) of the samples had 29% probability of being toxic.In contrast, the contamination severity indexes (CSI) ranged from 0.17 to 2.11, indicating a very low to moderate probability toxicity.Factor anal. indicated that chem. weathering, with 57% of the total variance, was the dominant factor controlling the soil geochem. followed by artisanal gold mining (10%) and farming (9%).Thus, weathering was the major contributor to heavy metal loading including Ni, Cr and As.Among heavy metals, only Cr, Ni, As and Ba posed non-cancerogenic (THI >1) and cancerogenic (TCR >1.0 x 10^-4) risks to the exposed population with children being the most vulnerable.In the absence of prior knowledge of the soil geochem. status, the heavy metals may be redistributed in the soil environment, and thereby compromising human health.

2025-12-25·Oriental Journal of Chemistry

Eco-Friendly Fabrication of Polymer Encapsulated Gold Nanoparticles with Anticancer and Antimicrobial Activities

作者: Chaudhary, Mansi ; Chaudhary, Leela ; Patel, Nidhi ; Parmar, Kokila A. ; Makvana, Chirag ; Moga, Himani

Polyvinylpyrrolidone (PVP) encapsulated gold nanoparticles (AuNPs) have gained significant attention in biomedical research due to their unique physicochemical and therapeutic properties. This study outlines an eco-friendly approach for synthesizing PVP-AuNPs using Gymnema sylvestre extract as a natural reducing agent. By optimizing the extract to HAuCl₄ ratio, effective synthesis was achieved at a 3.0% extract concentration producing spherical AuNPs with an average size of 33 nm as confirmed by transmission electron microscopy (TEM). Fourier transform infrared spectroscopy (FTIR) analysis validated the successful encapsulation of AuNPs with PVP revealing characteristic peaks corresponding to PVP and functional groups from the plant extract. Furthermore, X-ray diffraction (XRD) patterns confirmed the crystalline nature of the synthesized AuNPs. The PVP-AuNPs exhibited cytotoxic activity against HeLa cancer cells, with an IC₅₀ value of 32.42 μg/mL after 48 hours. Additionally, the nanoparticles demonstrated significant bactericidal activity against pathogens such as Pseudomonas aeruginosa, Escherichia coli, Bacillus subtilis, and Staphylococcus aureus, showing concentration-dependent antimicrobial effects. This work underscores the potential of green-synthesized PVP-AuNPs as a versatile platform for cancer therapy and antimicrobial applications providing a sustainable pathway to advancements in nanomedicine.

2025-12-16·INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY

Development of a chitosan-gold nanocomposite based disposable pencil graphite electrode for the selective detection of thiram in peach juice

作者: Aslan, Nazife ; Şen, Nilgün ; Akan, Melike

Hazardous chems. that are mostly employed in modern agriculture for pest management have caused long-term environmental accumulation as well as major issues with food safety and human health.So, there is an urgent demand for efficient detection methods for environmental monitoring.To do this, the most contemporary electrochem. sensor technol. is suggested.In this study, a new electrochem. sensor has been developed to detect thiram (Th) fungicide, utilizing a modified activated pencil graphite electrode (a-PGE) made from chitosan-gold nanoparticle polymer (Ch-AuNPs) for the first time.The Ch-AuNPs/a-PGE surface has been characterised using cyclic voltammetry (CV), SEM (SEM), and energy dispersive X-ray spectroscopy (EDS).Following adjustments to exptl. parameters, the proposed electrochem. sensor demonstrated a linear calibration curve within the range of 4.90-140 μM, displaying a rapid response to thiram with a detection limit of 1.15 μM.The sensor exhibited notable selectivity, stability, and reproducibility.To assess its practical utility, the sensor was applied to analyze thiram in peach juice, and the recovery process indicated its effectiveness as a practical, swift, and efficient tool in pesticide residue monitoring.

166

项与 CNM-Au8 相关的新闻（医药）

2025-12-03

·EndPoints

Orion's €180M milestone payment; Iolyx partners dry eye candidate

Plus, news about QurAlis, Clene, ADC Therapeutics and Junevity: 💶 Orion to receive €180M milestone payment: The cash will come from Bayer, on the back of sales of prostate cancer therapy Nubeqa. Subsequently, Orion also updated its full-year sales outlook. — Reynald Castaneda 👁️ Iolyx finds a partner, raises money: California biotech Iolyx Therapeutics has nabbed a $15 million Series B from Frazier Life Sciences and GC&H. The startup also forged a partnership with Laboratoires Théa that is worth up to $280 million. Théa will get exclusive worldwide rights outside Asia to develop and market ILYX-002 for ocular surface diseases. Théa will run Phase 3 studies. The small biotech disclosed Phase 2 data in autoimmune dry eye disease in May. — Kyle LaHucik 💰 QurAlis gets another $25M: The Cambridge, MA-based biotech reeled in the money from existing investors, CEO Kasper Roet exclusively told Endpoints News . The biotech last disclosed an $88 million Series B in 2023 and a $45 million upfront neuro deal with Lilly in 2024. With extra runway from the insider round money, QurAlis has now pushed out its Series C raise until after its STMN2 data readout in the first half of 2026, Roet said. The experimental medicine, dubbed QRL-201, is in a proof-of-concept trial in ALS. The biotech also has investigational drugs for rare epilepsy, pain, Fragile X and other indications. — Kyle LaHucik 📊 Clene presents analyses for ALS drug, to seek FDA meeting: The biotech is developing a treatment based on gold nanocrystals to treat ALS. Researchers revealed three post-hoc analyses claiming to show its drug provided a benefit on biomarkers that could impact survival times. Clene is seeking accelerated approval for the drug, called CNM-Au8, and hopes to meet with regulators by the end of March 2026. In 2023, the FDA found Clene’s biomarker research to be “insufficient” to support approval. — Max Gelman 📊 ADC Therapeutics’ Zynlonta combo data: The biotech’s CD19-directed ADC in combination with Roche’s Columvi produced an overall response rate of almost 90% in patients with second-line or later relapsed or refractory diffuse large B cell lymphoma (DLBCL), including a 78% complete response rate. The open-label Phase 1b study had enrolled 49 DLBCL patients as of the November cutoff date. 💰 Junevity gets another $10M: The San Francisco startup expanded its seed round to develop an siRNA for type 2 diabetes and obesity. The money will get the biotech through “initial clinical studies,” Junevity said. The biotech anticipates entering Phase 1 in the second half of next year, and sees potential in pairing up with GLP-1s to reduce the dosing frequency of those blockbuster treatments. Investors include Goldcrest Capital and Godfrey Capital. — Kyle LaHucik

临床1期临床2期临床3期临床结果

2025-11-20

·invest.clene.com

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1x1 investor meetings. Conference DetailsDate: December 4, 2025Location: New York, New YorkFormat: 1x1 meetings (contact your Benchmark Representative) About CleneClene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn. Investor ContactKevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com617-283-2856

2025-11-13

·山与海的成长

神经退行性疾病详细介绍，全球现状和未来趋势？

一、神经退行性疾病详细介绍神经退行性疾病是一类因神经元结构或功能逐渐丧失而导致的慢性、进行性神经系统疾病，主要影响老年人，常见类型包括： 1. 阿尔茨海默病（AD）：最常见的痴呆类型，占病例的60%-80%，以β-淀粉样蛋白沉积、tau蛋白缠结和神经元丢失为特征，表现为记忆力减退、认知功能障碍和行为异常。 2. 帕金森病（PD）：第二大神经退行性疾病，因黑质多巴胺能神经元死亡导致，症状包括震颤、肌强直、运动迟缓等，50岁后发病率显著上升。 3. 肌萎缩侧索硬化症（ALS）：运动神经元进行性退化，导致肌肉无力、吞咽困难，最终呼吸衰竭，平均生存期3-5年。 4. 额颞叶痴呆（FTLD）：以额叶和颞叶萎缩为特征，表现为行为异常、语言障碍，多见于60岁以下人群。 5. 亨廷顿病（HD）：遗传性疾病，由HTT基因突变导致，表现为舞蹈样动作、认知衰退和精神症状。病理机制：衰老、基因突变、蛋白质稳态失衡（如Aβ、α-突触核蛋白异常积累）、线粒体功能障碍和神经炎症是核心因素。例如，AD中的β-淀粉样蛋白沉积引发神经炎症，破坏神经元网络；PD中的α-突触核蛋白聚集导致多巴胺能神经元死亡。治疗现状：目前缺乏根治方法，主要依赖对症治疗。例如，AD使用胆碱酯酶抑制剂改善认知，PD通过多巴胺替代疗法缓解症状。新兴技术如基因治疗（如CRISPR修复突变）、干细胞疗法（如iPS细胞分化为多巴胺神经元）和AI药物设计正在临床试验中，但尚未广泛应用。二、全球神经退行性疾病基本现状与未来趋势 1. 中国现状：老龄化加速，神经退行性疾病负担全球最重。预计2050年帕金森病患者将达1050万，占全球41.6%，年龄标准化患病率全球第一（583例/10万人）。阿尔茨海默病患者超1000万，且以每年30万速度递增。治疗以仿制药为主（如左旋多巴、多奈哌齐），但本土创新崛起，如睿健医药、神济昌华通过AI+化学诱导平台开发帕金森病细胞疗法，恒瑞医药布局PROTAC技术。政策支持：将阿尔茨海默病纳入医保特殊病种，“十四五”规划推动基因编辑、干细胞等技术研发。未来趋势：人口老龄化持续加剧，预计2050年60岁以上人口占比超35%，疾病负担将进一步加重。精准医疗与创新药研发加速，如间充质干细胞治疗AD和PD的临床试验已启动（中部战区总医院），计划2028年完成随访。整合医学模式兴起，强调早期筛查（如血液生物标志物检测）和社区支持，降低家庭照料压力。 2. 日本现状：全球老龄化最严重国家，65岁以上人口占比超32%，神经退行性疾病患者数量庞大。家族性阿尔茨海默病（FAD）患者约100人，发病早、进展快。再生医学全球领先，京都大学iPS细胞研究所利用患者iPS细胞生成多巴胺神经元治疗PD，2024年临床试验显示5/7患者运动功能改善。药物再利用策略突破，如帕金森病药物溴氪被发现可减少FAD患者β-淀粉样蛋白沉积，2025年进入III期临床试验。未来趋势：依托iPS细胞技术推进个性化治疗，计划2028年将PD细胞疗法商业化。扩大临床试验规模，如溴氪针对FAD的III期试验覆盖全国多家医院，目标2028年获批。应对老龄化挑战，开发远程监测和居家护理技术，缓解医疗资源压力。 3. 美国现状：神经退行性疾病医疗支出全球最高，2021年痴呆症相关费用达3550亿美元，预计2050年将超1万亿美元。研发投入领先，NIH 2026财年为阿尔茨海默病研究拨款39亿美元，重点支持生物标志物发现、基因治疗和生活方式干预。药物审批加速，如Aβ单抗药物Aducanumab和Lecanemab获批上市，虽疗效有限但推动行业信心。未来趋势：加大罕见病研究，如NIH通过《加速获得ALS关键治疗法案》资助Clene Inc.的CNM-Au8疗法，2025年进入扩大准入阶段。人工智能深度应用，如谷歌Isomorphic Labs利用AI设计药物，首款针对神经退行性疾病的候选分子计划2025年底进入临床。整合公私合作，如NIH与药企联合开展“阿尔茨海默病预防计划”，探索早期干预策略。 4. 加拿大现状：人口老龄化显著，65岁以上人口占比19%，预计2050年达25%。阿尔茨海默病患者超74万，护理资源紧张。长期护理体系依赖公共资金，如魁北克省CHSLD机构提供免费医疗服务，但非医疗费用需个人承担，低收入家庭负担沉重。研究聚焦数据共享，如安大略省ONDRI项目整合5种神经退行性疾病数据，推动早期诊断和个性化治疗。未来趋势：联邦与省协作推进全国痴呆战略，如2019年拨款5000万加元支持社区服务，但各省政策差异大（如安大略省ALS护理资源不足）。基因治疗突破，如SickKids医院针对罕见病SPG50的单患者基因疗法显著延缓病情，为超罕见病治疗提供范式。技术赋能护理，如紧急呼叫手环、远程医疗等降低居家养老风险，但护工短缺问题亟待解决。 5. 欧盟现状：神经退行性疾病患者超1500万，医疗支出占GDP的1.2%，东欧国家资源匮乏（如罗马尼亚每10万人仅1.3名神经科医生）。政策协调与数据共享：EPND平台整合60多个队列的12万患者数据，加速生物标志物发现；NEURONET促进18个IMI项目协同，推动药物研发。药物审批高效，集中审批程序（CP）覆盖创新药和先进疗法，如基因治疗药物Zolgensma快速获批，但成员国间可及性差异显著（如保加利亚MS药物覆盖率84%，罗马尼亚仅60%）。未来趋势：深化跨国合作，如JPND联合24国制定战略研究议程，2025年启动精准医疗项目，探索多组学驱动的治疗方案。应对区域差异，通过“健康联盟”计划向东欧国家提供技术援助，扩大移动记忆团队和远程诊断覆盖。伦理与监管并重，如EMA建立基因治疗长期随访机制，确保安全性和疗效。三、全球共同挑战与解决方案 1. 老龄化加剧：2050年全球60岁以上人口将达21亿，神经退行性疾病患者数量预计翻倍。需加强公共卫生干预，如推广健康生活方式（运动、地中海饮食）以降低风险。 2. 研发瓶颈：传统药物研发周期长、成功率低。AI、基因编辑和再生医学（如iPS细胞）是破局关键，需国际协作共享数据和资源（如EPND、JPND）。 3. 医疗资源不均：发达国家与发展中国家、城乡之间差距显著。需建立全球卫生援助机制，推广低成本筛查工具（如基于智能手机的认知测试）。 4. 护理负担沉重：全球超5000万家庭照料者面临心理和经济压力。政策应支持喘息服务、远程护理和社区支持网络。四、总结神经退行性疾病是全球老龄化背景下最严峻的公共卫生挑战之一。中国、日本、美国、加拿大和欧盟在疾病负担、研发投入和政策应对上各具特点，但共同趋势是：技术驱动创新：AI、基因编辑、干细胞疗法重塑治疗格局。精准医疗兴起：基于生物标志物的早期诊断和个性化治疗成为焦点。全球协作深化：数据共享、跨国研究和伦理框架构建加速进展。未来，需整合医学、技术和社会资源，实现从症状管理向疾病修正的跨越，改善患者生活质量并减轻社会负担。

细胞疗法基因疗法蛋白降解靶向嵌合体

100 项与 CNM-Au8 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	申请上市	美国	Clene Nanomedicine, Inc.	-
复发性多发性硬化	临床3期	澳大利亚	Clene Nanomedicine, Inc.	2020-10-22
原发性进行性多发性硬化	临床2期	美国	Clene Nanomedicine, Inc.	2019-12-19
继发进展型多发性硬化	临床2期	美国	Clene Nanomedicine, Inc.	2019-12-19
帕金森病	临床2期	美国	Clene Nanomedicine, Inc.	2019-12-19
复发-缓解型多发性硬化	临床2期	美国	Clene Nanomedicine, Inc.	2018-11-23
复发-缓解型多发性硬化	临床2期	美国	Clene Australia Pty Ltd.	2018-11-23
复发-缓解型多发性硬化	临床2期	澳大利亚	Clene Nanomedicine, Inc.	2018-11-23
复发-缓解型多发性硬化	临床2期	澳大利亚	Clene Australia Pty Ltd.	2018-11-23
复发-缓解型多发性硬化	临床2期	加拿大	Clene Nanomedicine, Inc.	2018-11-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03536559 (VISIONARY-MS, Company_Website) 人工标引	临床2期	多发性硬化症	-	CNM-Au8	遞窪襯獵鏇襯鹹獵憲淵(構窪鑰鑰築糧鬱廠襯壓) = 96% of participants who were LCLA responders, showing visual improvement, also demonstrated improvement in MRI DTI metrics (AD and/or MTR), evidencing repair and remyelination. 襯壓簾網簾觸選艱遞鏇 (鏇餘廠選繭範築鑰遞選 ) 更多	积极	2025-04-08
NCT04436497 \| NCT04414345 (Company_Website \| NEWS) 人工标引	临床2/3期	肌萎缩侧索硬化	-	CNM-Au8 30 mgCNM-Au8 30 mg (Regimen C)	餘願鬱憲窪鹹網範觸構(窪衊蓋築遞築壓衊顧鏇) = 餘獵製蓋選積膚淵鏇鹹醖憲獵艱範繭願繭廠壓 (襯積鏇範網積膚廠蓋獵 ) 更多	积极	2025-03-12
				Zilucoplan (Regimen A)	餘願鬱憲窪鹹網範觸構(窪衊蓋築遞築壓衊顧鏇) = 獵艱遞選鹽選範範糧網醖憲獵艱範繭願繭廠壓 (襯積鏇範網積膚廠蓋獵 ) 更多
NCT04297683 \| NCT04414345 (Pubmed) 人工标引	临床2/3期	肌萎缩侧索硬化	161	CNM-Au8 60 mg/30 mg	繭壓鑰衊築衊構醖願觸(餘製鏇鏇鹽簾製衊獵齋): RR = 0.97 (95% CI, 0.783 ~ 1.175) 更多	不佳	2025-02-17
				Placebo
NCT04098406 (RESCUE-ALS, CTgov)	临床2期	肌萎缩侧索硬化	45	Placebo (Placebo)	獵網夢糧齋鏇築簾鏇繭(齋醖鬱醖窪觸鹽襯蓋鬱) = 簾壓襯簾願製構衊壓艱餘襯鬱憲願醖齋齋廠壓 (鏇壓襯簾憲窪蓋齋積壓, 7.1) 更多	-	2024-07-03
				CNM-Au8 (30 mg CNM-Au8)	獵網夢糧齋鏇築簾鏇繭(齋醖鬱醖窪觸鹽襯蓋鬱) = 蓋淵襯襯觸憲鹹憲餘蓋餘襯鬱憲願醖齋齋廠壓 (鏇壓襯簾憲窪蓋齋積壓, 6.6) 更多
NCT03815916 (REPAIR-PD, CTgov)	临床2期	帕金森病	13	CNM-Au8	醖選壓觸鹹鹹窪築鑰鹹(選襯鹹鏇獵憲繭齋遞簾) = 餘糧醖構夢鹹糧鹽鹽鬱襯蓋餘襯壓憲艱襯壓觸 (製願蓋鑰築範衊窪糧膚, 0.79968) 更多	-	2024-05-16
NCT03536559 (VISIONARY-MS, GlobeNewswire) 人工标引	临床2期	复发性多发性硬化	55	CNM-Au8 30mg	範築齋糧鏇廠鹽製簾積(選遞繭顧膚艱齋衊鑰艱) = 膚衊艱築網醖夢鏇製夢遞構鬱襯顧醖選選範憲 (鬱衊鑰簾淵獵廠膚淵選, 5.0 ~ 12.4) 更多	积极	2024-02-29
NCT04414345 (CTgov)	临床2/3期	肌萎缩侧索硬化	161	CNM-Au8 (CNM-Au8)	醖鬱憲憲願餘膚憲鑰鑰(鑰鏇願製製淵糧選顧鑰) = 繭顧壓遞積顧積顧餘餘簾築淵餘選艱顧選憲淵 (餘憲願糧餘範繭壓壓鑰, 0.075) 更多	-	2023-07-25
				Matching Placebo (Matching Placebo)	醖鬱憲憲願餘膚憲鑰鑰(鑰鏇願製製淵糧選顧鑰) = 糧網築衊鹽製築獵鬱艱簾築淵餘選艱顧選憲淵 (餘憲願糧餘範繭壓壓鑰, 0.072) 更多
NCT04098406 (RESCUE-ALS, Pubmed)	临床2期	肌萎缩侧索硬化	45	CNM-Au8	獵鬱範夢築網鏇網顧簾(蓋醖襯廠醖願鹹蓋簾遞): hazard ratio = 0.408 (95% CI, 0.166 ~ 1.001), P-Value = 0.0429	积极	2023-06-01
				Placebo
NCT04098406 (RESCUE-ALS, Corporate Publications) 人工标引	临床2期	肌萎缩侧索硬化	45	CNM-Au8	鹽構鏇選積願窪衊廠鏇(糧壓膚窪鹽廠構構廠壓) = 鹹餘鑰蓋選觸積觸窪獵糧獵鹹壓齋鬱網膚獵鹽 (衊餘選醖觸夢夢蓋齋構 )	积极	2022-07-14
				Placebo	-
NCT04098406 (RESCUE-ALS, MDA2022)	临床2期	肌萎缩侧索硬化	45	CNM-Au8 30mg	襯遞餘製壓醖顧壓糧醖(醖範網簾顧壓鑰鏇鹽窪) = CNM-Au8 treatment was well-tolerated and there were no significant safety findings reported during the OLE 鏇齋蓋鹹顧觸觸鹽鏇壓 (積衊築夢願鑰鑰衊醖憲 ) 更多	积极	2022-03-13
				Placebo